Weight Loss Drugs Lawsuit
US$ 22.64
glp 1 injection site itching Initial presentation of the patient showing bilateral erythematous Rash from a GLP-1 explained
Description
Trop-Steinberg S et al
Patients should be informed of potential side effects and safety-netted appropriately in case these occur
doi: 10.1038/s41574-018-0118-x
Persons with or at risk for renal impairment should be counseled on strategies to prevent dehydration and monitored for changes in renal function
however, it is not yet approved for use Boehringer Ingelheim, a biopharmaceutical company headquartered in Ingelheim, Germany, has announced promising results from its Phase 3 SYNCHRONIZE-1 clinical trial testing survodutide
